About Event:

Your one-stop shop to capturing industry’s most exciting developments to tackle rare & genetic kidney diseases

From evaluating real-world outcomes to uncovering underlying pathophysiology to interrogating translational models, the 3rd Rare & Genetic Kidney Disease Drug Development Summit was uniquely positioned to give industry the opportunity to unite towards a shared goal and share strategic insights to move from bench to bedside and bring efficacious therapies to patients faster.

What You Missed:

icon 3
icon 2
icon 1
icon 4
icon 5

Amplifying patients’ voices with Takeda Pharmaceutical, Alport Syndrome Foundation, International Society of Glomerular Disease and Children’s National Hospital to better understand patients’ perspectives and experiences in clinical trials to optimise treatment

Aiding the development of clinical trials with Calliditas Therapeutics by understanding payers’ requirements to facilitate access to care for patients with orphan kidney diseases

Delineating the current and future scope of kidney gene therapy, protein replacement, RNA medicines and non-immunosuppressive therapy with Eloxx Pharmaceuticals, Travere Therapeutics, Eli Lilly and Purespring Therapeutics to illuminate the windows of opportunity for renal precision medicine

Highlighting the opportunities for the development of clinically effective biomarkers, including Anti-PLA2R with Chinook Therapeutics and Cerium Therapeutics to allow for early clinical development

Innovating clinical trial design by ensuring the evolvement of registries and enrolment of patients with Sanofi, Janssen Research & Development and Otsuka to improve patient access and treatment

Who Was There?

audience summary

What Your Peers Have to Say:

"This meeting can help understand several important aspects of drug development relevant to rare genetic diseases”


"This summit brings together diverse stakeholders for discussions around innovative research, clinical development, and regulatory science”